Evommune, Inc. (EVMN) Total Return Calculator with Dividends Reinvested

Evommune, Inc.

Popular:

The total return for Evommune, Inc. (EVMN) stock is +6.38% over the past 12 months. So far it's up 19.53% this year. The 5-year total return is +6.38%, meaning $10,000 invested in EVMN stock 5 years ago would be worth $10,638 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in EVMN 1 year ago, it would be worth $10,638 today — you'd have gained $638.

With Dividends Reinvested$10,638+6.38%

Price Only (No DRIP)$10,638+6.38%

Period2025-11-17 → 2026-06-11

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in EVMN

1Y$10,638+$638 (+6.4%)6.4% CAGR

3Y$10,638+$638 (+6.4%)2.1% CAGR

5Y$10,638+$638 (+6.4%)1.2% CAGR

10Y$10,637+$637 (+6.4%)0.6% CAGR

15Y$10,638+$638 (+6.4%)0.4% CAGR

20Y$10,638+$638 (+6.4%)0.3% CAGR

30Y$10,637+$637 (+6.4%)0.2% CAGR

Evommune, Inc. did not pay dividends during this period. Total return = price return.

Loading EVMN total return...

As of 2026-06-12

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+19.53%	—	+19.53%	—	$11,953
1Y	+6.38%	6.38%	+6.38%	—	$10,638
3Y	+6.38%	2.08%	+6.38%	—	$10,638
5Y	+6.38%	1.24%	+6.38%	—	$10,638
10Y	+6.37%	0.62%	+6.37%	—	$10,637
15Y	+6.38%	0.41%	+6.38%	—	$10,638
20Y	+6.38%	0.31%	+6.38%	—	$10,638
30Y	+6.37%	0.21%	+6.37%	—	$10,637

Risk & Highlights

Best Year-11.98%2025

Max Drawdown-37.50%2026-02-13 → 2026-06-03

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+50.20%	+50.20%	—	+0.41%	+49.8pp
2025	-11.98%	-11.98%	—	+16.64%	-28.6pp

EVMN underperformed the S&P 500 by 16.31pp over the past year (+6.38% vs +22.68%).

Loading summary...

EVMN Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
EVMNEvommune, Inc.	$652M	-10.9%	+19.5%	+6.4%	—	+6.4%	+6.4%	+6.4%
IMVTImmunovant, Inc.	$6.8B	+13.1%	+26.9%	+103.6%	—	+51.6%	+207.0%	+230.5%
ARDXArdelyx, Inc.	$1.4B	-12.4%	-5.9%	+56.5%	—	+45.1%	+213.0%	+166.8%
CLDXCelldex Therapeutics, Inc.	$2.0B	-7.2%	+10.9%	+46.7%	—	-19.2%	-3.5%	-50.7%
PRAXPraxis Precision Medicines, Inc.	$7.2B	-25.3%	-13.4%	+456.0%	—	+1628.1%	-17.6%	-40.5%
RAPTRAPT Therapeutics, Inc.	$296M	—	+82.1%	+559.1%	—	-64.8%	-61.0%	-44.2%
KYMRKymera Therapeutics, Inc.	$6.8B	-1.4%	+14.0%	+71.4%	—	+230.0%	+64.1%	+149.4%
REGNRegeneron Pharmaceuticals, Inc.	$63.5B	-14.2%	-21.0%	+18.6%	+0.7pp	-18.2%	+17.4%	+68.0%
ABBVAbbVie Inc.	$397.6B	+10.8%	-0.5%	+20.9%	+3.5pp	+77.1%	+121.1%	+357.3%
LLYEli Lilly and Company	$1.10T	+20.0%	+7.8%	+44.4%	+0.8pp	+164.5%	+429.1%	+1522.5%
NKTRNektar Therapeutics	$1.2B	-24.9%	+36.4%	+520.0%	—	+592.5%	-77.6%	-73.6%

Compare:EVMN vs IMVT EVMN vs ARDX EVMN vs CLDX EVMN vs IMVT vs ARDX

About EVMN Dividend Returns

Evommune, Inc. (EVMN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of EVMN over the past year?

Evommune, Inc. (EVMN) delivered a return of 6.38% over the past year. Since EVMN does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in EVMN be worth today?

A $10,000 investment in Evommune, Inc. one year ago would be worth $10,638 today, representing a gain of $638.

Q3Does EVMN pay dividends?

Evommune, Inc. (EVMN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For EVMN, the total return equals the price-only return.

Q4Did EVMN beat the S&P 500?

No, Evommune, Inc. (EVMN) underperformed the S&P 500 by 16.31 percentage points over the past year. EVMN delivered a total return of 6.38%, compared to the S&P 500's 22.68%. This means a passive S&P 500 index fund outperformed EVMN by 16.31pp during this period.

Q5What is EVMN's worst drawdown?

Evommune, Inc. (EVMN) experienced a maximum drawdown of -37.50% over the past year, declining from its peak on 2026-02-13 to its trough on 2026-06-03. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is EVMN's long-term total return over 10, 20, or 30 years?

Here are Evommune, Inc. (EVMN)'s long-term returns with dividends reinvested. Over 10 years, the total return is 6.4% (0.6% CAGR) — $10,000 would have grown to $10,637. Over 20 years: 6.4% total return (0.3% CAGR) — $10,000 → $10,638. Over 30 years: 6.4% total return (0.2% CAGR) — $10,000 → $10,637. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

How much would $100/month in EVMN be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →